DelveInsight Highlights Major Advances, Transformative Therapies, and 260+ Leading Players Wheeling the Acute Myeloid Leukemia Clinical Trial Pipeline Landscape
The Acute Myeloid Leukemia Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Acute Myeloid Leukemia treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the pipeline landscape and fostering the potential growth of Acute Myeloid Leukemia therapeutic advancements.
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
- DelveInsight’s Acute Myeloid Leukemia pipeline report depicts a robust space with 260+ active players working to develop 260+ pipeline therapies for Acute Myeloid Leukemia treatment.
- The leading companies working in the Acute Myeloid Leukemia market include GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and others.
- Promising Acute Myeloid Leukemia Pipeline Therapies in the various stages of development include OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
- On February 2023, Telios Pharma Inc. announced a study of Phase 1 & 2 clinical trials for TL-895 and KRT-232. This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small molecule inhibitor of MDM2 for the treatment of adults with FLT3 mutated Acute Myeloid Leukemia. Participants must be relapsed/refractory (e.g., having failed prior therapy) to be eligible for this study.
- On May 2023, Menarini Group announced a study of Phase 1 & 2 clinical trials for SEL24/MEN1703. The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia.
- On May 2023, Shijiazhuang Yiling Pharmaceutical Co. Ltd announced a study of Phase 1 clinical trials for XY0206. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML.
- On July 2023, AbbVie announced a study of Phase 3 clinical trials for Azacitidine, and Venetoclax. Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit. The effect of the treatment on AML will be checked by taking blood, bone marrow, scans, measuring side effects and by completing health questionnaires.
Request a sample and discover the recent advances in Acute Myeloid Leukemia Treatment Drugs @ Acute Myeloid Leukemia Infection Pipeline Report
The Acute Myeloid Leukemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Acute Myeloid Leukemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Acute Myeloid Leukemia clinical trial landscape.
Acute Myeloid Leukemia Overview
Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. It is characterized by clonal expansion of immature “blast cells” in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and bone marrow failure.
Find out more about Acute Myeloid Leukemia Treatment Drugs @ Drugs for Acute Myeloid Leukemia Treatment
Acute Myeloid Leukemia Emerging Drugs Profile
- Omidubicel: Gamida Cell
- Uproleselan: GlycoMimetics
- ALT 803: ImmunityBio
- BPX-501: Bellicum Pharmaceuticals
Acute Myeloid Leukemia Pipeline Therapeutics Assessment
There are approx. 260+ key companies which are developing the Acute Myeloid Leukaemia therapies. The Acute Myeloid Leukaemia companies which have their Acute Myeloid Leukaemia drug candidates in the most advanced stage, i.e preregistration include Gamida Cell.
Learn more about the emerging Acute Myeloid Leukemia Pipeline Therapies @ Acute Myeloid Leukemia Clinical Trials Assessment
Scope of the Acute Myeloid Leukemia Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Acute Myeloid Leukemia Companies- GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and others.
- Acute Myeloid Leukemia Pipeline Therapies- OCV-501, SEL24/MEN1703, Venetoclax, Alvocidib, TL-895, KRT-232, XY0206, Azacitidine, Venetoclax, and others.
Dive deep into rich insights for new drugs for Acute Myeloid Leukemia treatment, Visit @ Acute Myeloid Leukemia Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Acute Myeloid Leukaemia: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Acute Myeloid Leukaemia– DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Omidubicel: Gamida Cell
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase III)
- Uproleselan: GlycoMimetics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- ALT 803: ImmunityBio
- Early Stage Products (Phase I)
- JNJ-75276617: Janssen Research & Development, LLC
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- AB001: Agastiya Biotech
- Drug profiles in the detailed report…..
- Inactive Products
- Acute Myeloid Leukaemia Key Companies
- Acute Myeloid Leukaemia Key Products
- Acute Myeloid Leukaemia- Unmet Needs
- Acute Myeloid Leukaemia- Market Drivers and Barriers
- Acute Myeloid Leukaemia- Future Perspectives and Conclusion
- Acute Myeloid Leukaemia Analyst Views
- Acute Myeloid Leukaemia Key Companies
- Appendix
For further information on the Acute Myeloid Leukemia pipeline therapeutics, reach out @ Acute Myeloid Leukemia Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
